This website is intended for UK registered healthcare professionals (HCPs) only. Adverse event reporting can be found at the bottom

Enrolment form

As agreed with the Medicines and Healthcare Products Regulatory Agency (MHRA), a register of prescribers who have reviewed the additional Risk Minimisation Materials (aRMM) on the safety aspects of tolvaptan is being maintained. Otsuka Pharmaceuticals (U.K.) Ltd. will send notifications to all prescribers on the register about any material updates and will also issue an annual reminder to re-review the aRMM.

Fields marked with an asterisk (*) are mandatory.

About you

About your institution